At the recent ASH meeting, pharmaceutical company Eli Lily announced findings from their Phase I trial for LY2784544, a JAK2 inhibitor. They are developing this compound for the treatment of patients with JAK2 positive polycythemia vera, essential thrombocythemia or myelofibrosis. For more information please click here to be redirected to Eli Lily’s press release.
ELI LILY ANNOUNCES DATA FOR PHASE I OF JAK2 INHIBITOR TRIAL
MPNRF | April 30, 2021